| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S11910-005-0046-8 |
| P698 | PubMed publication ID | 15865884 |
| P50 | author | Patrick Y Wen | Q105531697 |
| P2093 | author name string | Santosh Kesari | |
| Charles D Stiles | |||
| Naren Ramakrishna | |||
| Claire Sauvageot | |||
| P2860 | cites work | Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme | Q27824801 |
| EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy | Q27824812 | ||
| Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma | Q27860910 | ||
| Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib | Q27861059 | ||
| PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration | Q28378001 | ||
| The contribution of epidermal growth factor receptor (EGFR) signaling pathway to radioresistance in human gliomas: a review of preclinical and correlative clinical data. | Q33198320 | ||
| Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated efflux | Q34179704 | ||
| Malignant glioma: genetics and biology of a grave matter. | Q34272357 | ||
| Effects of the proteasome inhibitor ritonavir on glioma growth in vitro and in vivo. | Q34301275 | ||
| Cannabinoids: potential anticancer agents | Q34542671 | ||
| Perspectives on the development of a molecularly targeted agent | Q34710684 | ||
| The molecular genetics of therapeutic resistance in malignant astrocytomas | Q34783074 | ||
| Signaling pathways regulating gliomagenesis | Q35056649 | ||
| Targeted molecular therapy of GBM. | Q35064179 | ||
| Genetic and signaling pathway alterations in glioblastoma relevance to novel targeted therapies | Q35109556 | ||
| Recent advances in the molecular genetics of primary gliomas | Q35141670 | ||
| Molecular analysis of glioblastoma: pathway profiling and its implications for patient therapy | Q35184074 | ||
| Role of radiation therapy and radiosurgery in glioblastoma multiforme | Q35210484 | ||
| Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas | Q44477258 | ||
| Geldanamycin inhibits migration of glioma cells in vitro: a potential role for hypoxia-inducible factor (HIF-1alpha) in glioma cell invasion | Q44481486 | ||
| Phase II trial of gefitinib in recurrent glioblastoma | Q44669178 | ||
| Phase I/pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugs. | Q45006311 | ||
| Phase II study of concurrent continuous Temozolomide (TMZ) and Tamoxifen (TMX) for recurrent malignant astrocytic gliomas | Q45139628 | ||
| Somatic mutations of EGFR in colorectal cancers and glioblastomas | Q45206490 | ||
| Clinical and radiographic response in a minority of patients with recurrent malignant gliomas treated with high-dose tamoxifen | Q46090896 | ||
| Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. | Q46410598 | ||
| Long-term inhibition of glioma growth by systemic administration of human PEX. | Q47383757 | ||
| Gene expression profiling identifies molecular subtypes of gliomas | Q47719947 | ||
| Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. | Q47999142 | ||
| Salvage chemotherapy with tamoxifen for recurrent anaplastic astrocytomas | Q48186613 | ||
| Expression of cyclooxygenase 2 (COX-2) in human glioma and in vitro inhibition by a specific COX-2 inhibitor, NS-398. | Q55475169 | ||
| Malignant gliomas | Q79969984 | ||
| Immunohistochemical detection of EGFRvIII in high malignancy grade astrocytomas and evaluation of prognostic significance | Q80410939 | ||
| Histone deacetylase inhibitors | Q80489191 | ||
| Anti-epidermal growth factor receptor monoclonal antibody cetuximab augments radiation effects in glioblastoma multiforme in vitro and in vivo | Q81194639 | ||
| The molecular target of rapamycin (mTOR) as a therapeutic target against cancer | Q35542821 | ||
| Invasion as limitation to anti-angiogenic glioma therapy | Q35553151 | ||
| Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors. Part 1: growth factor and Ras signaling pathways | Q35576159 | ||
| Farnesyltransferase inhibitors and their potential in the treatment of breast carcinoma | Q35581809 | ||
| Advances in gene therapy and immunotherapy for brain tumors | Q35587053 | ||
| Cell-cycle targeted therapies | Q35618786 | ||
| Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors. Part 2: PI3K/Akt/PTEN, mTOR, SHH/PTCH and angiogenesis | Q35641225 | ||
| Cyclooxygenase-2 inhibitors in glioma therapy | Q35681766 | ||
| Anti-angiogenic chemotherapy in central nervous system tumors. | Q35688578 | ||
| Molecular targeting for malignant gliomas (Review). | Q35739418 | ||
| The proteasome: a suitable antineoplastic target | Q35762448 | ||
| Development of novel targeted therapies in the treatment of malignant glioma | Q35770177 | ||
| A review of the proteasome inhibitor bortezomib in multiple myeloma | Q35784057 | ||
| Characterization of gene expression profiles associated with glioma progression using oligonucleotide-based microarray analysis and real-time reverse transcription-polymerase chain reaction | Q35792015 | ||
| PDGF receptors-mediators of autocrine tumor growth and regulators of tumor vasculature and stroma | Q35811104 | ||
| DNA-microarray analysis of brain cancer: molecular classification for therapy | Q35892040 | ||
| Antiangiogenic therapy for primary and metastatic brain tumors | Q35913186 | ||
| Therapy for recurrent malignant glioma in adults | Q35918439 | ||
| Molecular neuro-oncology and the development of targeted therapeutic strategies for brain tumors. Part 3: brain tumor invasiveness | Q35918449 | ||
| Targeted molecular therapy for malignant gliomas | Q35930279 | ||
| Hsp90 activation and cell cycle regulation | Q35946757 | ||
| A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors. | Q37089440 | ||
| SB-431542, a small molecule transforming growth factor-beta-receptor antagonist, inhibits human glioma cell line proliferation and motility. | Q38339796 | ||
| Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition. | Q40469450 | ||
| Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. | Q40479307 | ||
| Agents with selective estrogen receptor (ER) modulator activity induce apoptosis in vitro and in vivo in ER-negative glioma cells. | Q40479892 | ||
| Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors | Q40550209 | ||
| Inhibition of glioma angiogenesis and invasion by SI-27, an anti-matrix metalloproteinase agent in a rat brain tumor model | Q40562023 | ||
| Mutant epidermal growth factor receptor displays increased signaling through the phosphatidylinositol-3 kinase/AKT pathway and promotes radioresistance in cells of astrocytic origin | Q40568043 | ||
| Plasminogen activator inhibitor-1 increases the expression of VEGF in human glioma cells | Q40586601 | ||
| Flavopiridol inhibits the growth of GL261 gliomas in vivo: implications for malignant glioma therapy | Q40601313 | ||
| LY317615 decreases plasma VEGF levels in human tumor xenograft-bearing mice | Q40620827 | ||
| Thalidomide as an anti-angiogenic agent in relapsed gliomas | Q40708350 | ||
| Inhibition of glioma growth in vivo by selective activation of the CB(2) cannabinoid receptor. | Q40789377 | ||
| Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials | Q40789890 | ||
| Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor/medulloblastoma models as single agent and in combination chemotherapy. | Q40821386 | ||
| SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types | Q42820704 | ||
| Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class. | Q42835356 | ||
| Preferential susceptibility of brain tumors to the antiangiogenic effects of an alpha(v) integrin antagonist | Q43517798 | ||
| Disruption of the EF-2 kinase/Hsp90 protein complex: a possible mechanism to inhibit glioblastoma by geldanamycin. | Q43612272 | ||
| Cyclooxygenase-2 expression in human gliomas: prognostic significance and molecular correlations | Q43627781 | ||
| Phase II study of thalidomide in the treatment of recurrent glioblastoma multiforme | Q43837751 | ||
| Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme | Q43899658 | ||
| Microglia cyclooxygenase-2 activity in experimental gliomas: possible role in cerebral edema formation. | Q44308458 | ||
| Propylthiouracil-induced chemical hypothyroidism with high-dose tamoxifen prolongs survival in recurrent high grade glioma: a phase I/II study. | Q44393345 | ||
| Analysis of the phosphatidylinositol 3'-kinase signaling pathway in glioblastoma patients in vivo | Q44462995 | ||
| P433 | issue | 3 | |
| P304 | page(s) | 186-197 | |
| P577 | publication date | 2005-05-01 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | Current Neurology and Neuroscience Reports | Q18206211 |
| P1476 | title | Targeted molecular therapy of malignant gliomas. | |
| P478 | volume | 5 |
| Q40092579 | Array CGH in Brain Tumors |
| Q64235666 | Bioinformatics Analysis of Key Genes and Pathways for Medulloblastoma as a Therapeutic Target |
| Q37225840 | Biomarkers of clinical responsiveness in brain tumor patients : progress and potential |
| Q26865911 | Current Understanding on EGFR and Wnt/β-Catenin Signaling in Glioma and Their Possible Crosstalk |
| Q42380833 | Daam2 driven degradation of VHL promotes gliomagenesis. |
| Q38774306 | Effect of brefelamide on HGF-induced survival of 1321N1 human astrocytoma cells |
| Q39953614 | Efficacy of the HSP90 inhibitor 17-AAG in human glioma cell lines and tumorigenic glioma stem cells |
| Q37494827 | Fibulin-3 Promotes Glioma Growth and Resistance through a Novel Paracrine Regulation of Notch Signaling |
| Q79811506 | Medical management of patients with brain tumors |
| Q37037132 | Molecular diagnostic testing in malignant gliomas: a practical update on predictive markers |
| Q34815207 | Molecular pathology in adult gliomas: diagnostic, prognostic, and predictive markers |
| Q37198942 | Neural stem cells secrete factors facilitating brain regeneration upon constitutive Raf-Erk activation |
| Q36642473 | Overexpression of SSAT by DENSPM treatment induces cell detachment and apoptosis in glioblastoma |
| Q24297584 | PKC-ι promotes glioblastoma cell survival by phosphorylating and inhibiting BAD through a phosphatidylinositol 3-kinase pathway |
| Q30441458 | Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults. |
| Q30439565 | Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults |
| Q38466732 | Phosphodiesterase inhibitors control A172 human glioblastoma cell death through cAMP-mediated activation of protein kinase A and Epac1/Rap1 pathways |
| Q96231183 | Receptor tyrosine kinase targeting in glioblastoma: performance, limitations and future approaches |
| Q39453904 | Regulation of Cdk7 activity through a phosphatidylinositol (3)-kinase/PKC- -mediated signaling cascade in glioblastoma |
| Q39440979 | Resveratrol downregulates PI3K/Akt/mTOR signaling pathways in human U251 glioma cells. |
| Q54964048 | Significant Effect of Anti-tyrosine Kinase Inhibitor (Gefitinib) on Overall Survival of the Glioblastoma Multiforme Patients in the Backdrop of Mutational Status of Epidermal Growth Factor Receptor and PTEN Genes. |
| Q37908815 | Towards tailored therapy of glioblastoma multiforme |
Search more.